Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H15FN2.ClH |
| Molecular Weight | 266.742 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1(CC2=CC=C(F)C=C2C1)C3=CNC=N3
InChI
InChIKey=XAGTWPPXXHAZMK-UHFFFAOYSA-N
InChI=1S/C14H15FN2.ClH/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14;/h3-5,8-9H,2,6-7H2,1H3,(H,16,17);1H
Fipamezole is a fluorine substituted imidazole compound with high antagonist specificity for the presynaptic alpha2-adrenoceptor. There were no significant differences between the affinity of Fipamezole for the different subtypes, thus characterizing Fipamezole as a non-subtype–selective alpha2 antagonist. Fipamezole had been in phase III clinical trials for the treatment of dyskinesia associated with Parkinson’s disease. Detected side effects are hypertension, nausea, vomiting, dysgeusia, facial flushing.
CNS Activity
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
441J9148CQ
Created by
admin on Sat Dec 16 05:00:20 GMT 2023 , Edited by admin on Sat Dec 16 05:00:20 GMT 2023
|
PRIMARY | |||
|
150586-72-4
Created by
admin on Sat Dec 16 05:00:20 GMT 2023 , Edited by admin on Sat Dec 16 05:00:20 GMT 2023
|
PRIMARY | |||
|
6918257
Created by
admin on Sat Dec 16 05:00:20 GMT 2023 , Edited by admin on Sat Dec 16 05:00:20 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
